Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia.
Brandão LR, Tartakovsky I, Albisetti M, Halton J, Bomgaars L, Chalmers E, Luciani M, Saracco P, Felgenhauer J, Lvova O, Simetzberger M, Sun Z, Mitchell LG. Brandão LR, et al. Among authors: halton j. Blood Adv. 2022 Nov 22;6(22):5908-5923. doi: 10.1182/bloodadvances.2021005681. Blood Adv. 2022. PMID: 36150047 Free PMC article. Clinical Trial.
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
Brandão LR, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Svirin P, Kuhn T, Zapletal O, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Brueckmann M, Luciani M; DIVERSITY Study Investigators. Brandão LR, et al. Among authors: halton j. Blood. 2020 Feb 13;135(7):491-504. doi: 10.1182/blood.2019000998. Blood. 2020. PMID: 31805182 Free PMC article. Clinical Trial.
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Halton J, Brandão LR, Luciani M, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Sharathkumar A, Svirin P, Gorbatikov K, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Reilly P, Brueckmann M, Albisetti M; DIVERSITY Trial Investigators. Halton J, et al. Lancet Haematol. 2021 Jan;8(1):e22-e33. doi: 10.1016/S2352-3026(20)30368-9. Epub 2020 Dec 5. Lancet Haematol. 2021. PMID: 33290737 Clinical Trial.
Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism.
Albisetti M, Biss B, Bomgaars L, Brandão LR, Brueckmann M, Chalmers E, Gropper S, Harper R, Huang F, Luciani M, Manastirski I, Mitchell LG, Tartakovsky I, Wang B, Halton JML. Albisetti M, et al. Res Pract Thromb Haemost. 2018 Mar 25;2(2):347-356. doi: 10.1002/rth2.12086. eCollection 2018 Apr. Res Pract Thromb Haemost. 2018. PMID: 30046738 Free PMC article.
Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design.
Luciani M, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Chalmers E, Gropper S, Halton JML, Harper R, Huang F, Manastirski I, Mitchell LG, Tartakovsky I, Wang B, Brandão LR. Luciani M, et al. Res Pract Thromb Haemost. 2018 Apr 24;2(3):580-590. doi: 10.1002/rth2.12093. eCollection 2018 Jul. Res Pract Thromb Haemost. 2018. PMID: 30046763 Free PMC article.
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
Halton JML, Picard AC, Harper R, Huang F, Brueckmann M, Gropper S, Maas H, Tartakovsky I, Nurmeev I, Mitchell LG, Brandão LR, Chalmers E, Albisetti M. Halton JML, et al. Thromb Haemost. 2017 Nov;117(11):2168-2175. doi: 10.1160/TH17-06-0429. Epub 2017 Nov 30. Thromb Haemost. 2017. PMID: 29202215 Clinical Trial.
130 results